All In Biotech

Drug Trial Radar · NCT02710409

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

A Double-blind,Randomized,Positive-controlled, Non-inferiority Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Chinese Subjects Aged 3 Years and Older

Last checked: Nov 20, 2026Latest source record: Sep 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,664 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,664

Actual

Start

Jan 2016

Primary completion

Jun 2016

Study completion Aug 2016

Sponsor

Sponsor type
Research network
Collaborators
Jiangsu Jindike Biotechnology Co., Ltd.
First posted
Mar 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality. In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.

Conditions

  • Influenza

Interventions

  • Quadrivalent influenza vaccineBiological

    0.5 ml/vial, one dose, intramuscular injection on day 0

  • Trivalent influenza vaccine ABiological

    0.5 ml/vial, one dose, intramuscular injection on day 0

  • Trivalent influenza vaccine BBiological

    0.5 ml/vial, one dose, intramuscular injection on day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the 95% confidence interval (CI) lower limit for the seroconversion against each corresponding flu strain after vaccination is≥40% in subjects aged 3-59 years and≥30% in subjects aged ≥60 years separatelyTime frame: 28 days after vaccination
  2. incidence of solicited adverse reactions after vaccinationTime frame: 0-7 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guanyun County Center for Disease Control and Prevention

    Lianyungang, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.